5-({2-[(2-Fluorophenyl)methoxy]phenyl}methylidene)-2-sulfanylidene-1,3-diazinane-4,6-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-({2-[(2-Fluorophenyl)methoxy]phenyl}methylidene)-2-sulfanylidene-1,3-diazinane-4,6-dione
• 英文别名: 5-[[2-[(2-fluorophenyl)methoxy]phenyl]methylidene]-2-sulfanylidene-1,3-diazinane-4,6-dione
• 化学式: C₁₈H₁₃FN₂O₃S
• mdl: MFCD01571777
• 分子量: 356.4
• InChiKey: WPSGUGQHEVYVNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  99.5
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• Inhibition of SGK1 in the treatment of heart conditions
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：US10456398B2

  公开（公告）日：2019-10-29

  The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.

  本发明涉及通过抑制 SGK1 治疗受试者的获得性和遗传性心脏疾病，包括长 QT 综合征和心血管疾病，包括扩张型心肌病。可通过抑制 SGK1 治疗的心血管疾病包括心力衰竭、心律失常、缺血性损伤、缺血性梗塞、心脏纤维化、血管增生、血管再狭窄、扩张型心肌病和支架失效。本发明还确定了 SGK1 的选择性抑制剂。该方法包括向受试者施用治疗有效量的 SG 抑制剂。
• BARBITURIC ACID ANALOGS AS THERAPEUTIC AGENTS
  申请人：Novuspharma S.p.A.

  公开号：EP1305026B1

  公开（公告）日：2009-05-13
• SGK1 INHIBITORS IN THE TREATMENT OF LONG QT SYNDROME
  申请人：Beth Israel Deaconess Medical Center, Inc.

  公开号：EP3049085B9

  公开（公告）日：2021-08-18
• INHIBITION OF SGK1 IN THE TREATMENT OF HEART CONDITIONS
  申请人：BETH ISRAEL DEACONESS MEDICAL CENTER, INC.

  公开号：US20160243120A1

  公开（公告）日：2016-08-25

  The present invention relates to the treatment of acquired and genetic heart conditions in a subject by the inhibition of SGK1, including Long QT syndrome and cardiovascular disease, including dilated cardiomyopathy. Cardiovascular diseases treatable by SGK1 inhibition include heart failure, arrhythmia, ischemic injury, ischemic infarction, cardiac fibrosis, vascular proliferation, restenosis, dilated cardiomyopathy, and stent failure. The present invention also identifies selective inhibitors of SGK1. The method comprises administering to the subject a therapeutically effective amount of an inhibitor of SG.
• US9974788B2
  申请人：——

  公开号：US9974788B2

  公开（公告）日：2018-05-22